Advances in research on resistance to targeted therapy in BRAF-mutant thyroid cancer
- VernacularTitle:BRAF突变型甲状腺癌靶向治疗耐药的研究进展
- Author:
Lin GENG
1
;
Linfei HU
;
Xianhui RUAN
;
Xiangqian ZHENG
Author Information
- Keywords: BRAF mutation; thyroid cancer; targeted therapy; drug resistance
- From: Journal of Xi'an Jiaotong University(Medical Sciences) 2024;45(1):55-61
- CountryChina
- Language:Chinese
- Abstract: As the most common endocrine malignant tumor,the incidence rate of thyroid cancer is increasing year by year.However,the vast majority of subtypes have a good prognosis after traditional surgery,TSH suppression therapy and 131I treatment.With the progressive development of modern medicine,for a few thyroid cancers with poor effects of traditional treatment,molecular diagnosis and targeted therapy have further enriched the therapeutic means of thyroid cancer,in which BRAF mutation is widely present in thyroid cancer,but it often shows primary resistance or poor response to 131I therapy.The factors leading to primary or secondary resistance to targeted drugs with BRAF mutation may include genomic instability,expansion of resistant clones,occurrence of intrinsic mutations,or novel genetic and epigenetic alterations.In this article,we will review the research progress in targeted therapy resistance in BRAF-mutant thyroid cancer.
